<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2972">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01453946</url>
  </required_header>
  <id_info>
    <org_study_id>D9422C00002</org_study_id>
    <nct_id>NCT01453946</nct_id>
  </id_info>
  <brief_title>Safety and Maintenance Study of Entocort for Children With Crohn's Disease</brief_title>
  <official_title>A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Germany: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Safety for Maintenance of Entocort EC for children with mild to moderate Crohn's Disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multicenter, Open label, Non-comparative Study to Evaluate the Safety of Entocort EC as a
      Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years,
      Inclusive
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Any kind of adverse event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PCDAI</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pediatric Crohn's Disease Activity Index. The scale ranges from 0 (no activity) to 100 (high activity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IMPACT 3</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>IMPACT-III - A QUALITY OF LIFE QUESTIONNAIRE FOR CHILDREN WITH INFLAMMATORY BOWEL DISEASE</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Entocort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Study Medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entocort</intervention_name>
    <description>Entocort capsules, taken orally, 6 mg daily.</description>
    <arm_group_label>Entocort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All male and female subjects must be aged 5 to 17, inclusive, and must not have
             reached their 18th birthday by the estimated final office visit.

          -  All subjects must weight &gt;= 15 kg at the time of enrollment.

          -  Subjects must have been diagnosed and treated for active Crohn's disease of the ileum
             and/or ascending colon confirmed by endoscopic and/or radiographic evidence, and/or
             evidence of mucosal erosions and/or histology and have a PCDAI &lt;= 10

        Exclusion Criteria:

          -  Subjects who have had any previous intestinal resection proximal to and including the
             ascending colon.

          -  Subjects with evidence of active Crohn's disease (PCDAI &gt; 10) and/or stricturing,
             prestenotic dilatation, clinical evidence of obstruction, perirectal abscess,
             perirectal disease with active draining fistulas, perforation, or any septic
             complications.

          -  Subjects with morning cortisol level &lt;150 nmol/l (5.4 ug/dl) or DHEA-S below normal
             range for age and gender (NOTE: Subjects from the induction protocol with abnormal
             morning cortisol/DHEA-S levels at Visit 4, who otherwise meet the eligibility
             criteria, may be enrolled if the investigator decides that Entocort 6 mg is an
             appropriate therapy option.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanley Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Center for Digestive Healthcare, LLC, Atlanta, Georgia, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan Eklund, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca Pharmaceuticals, Mölndal, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mays Landing</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nürnberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rzeszów</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=649&amp;filename=ADMIRe_D9422C00002_CTD_Synopsis.pdf</url>
    <description>CSR Synopsis</description>
  </link>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 3, 2015</lastchanged_date>
  <firstreceived_date>October 14, 2011</firstreceived_date>
  <firstreceived_results_date>February 11, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's Disease</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In this study, 55 patients were enrolled but only 50 fulfilled the enrolment criteria.</recruitment_details>
      <pre_assignment_details>55 patients were enrolled but only 50 received treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Entocort</title>
          <description>Entocort 6 mg/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not receive drug for the taper phase</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entocort</title>
          <description>Entocort 6 mg/day</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="50"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="13.8" lower_limit="8" upper_limit="17"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=8 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;8 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="48"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="45"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or african american</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>PCDAI</title>
        <description>Pediatric Crohn's Disease Activity Index. The scale ranges from 0 (no activity) to 100 (high activity)</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Entocort</title>
            <description>Entocort 6 mg/day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="49"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>PCDAI</title>
            <description>Pediatric Crohn's Disease Activity Index. The scale ranges from 0 (no activity) to 100 (high activity)</description>
            <units>Scores on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.9" spread="3.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change after 12 weeks</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" spread="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>12 weeks</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.9" spread="8.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IMPACT 3</title>
        <description>IMPACT-III - A QUALITY OF LIFE QUESTIONNAIRE FOR CHILDREN WITH INFLAMMATORY BOWEL DISEASE</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Entocort</title>
            <description>Entocort 6 mg/day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>IMPACT 3</title>
            <description>IMPACT-III - A QUALITY OF LIFE QUESTIONNAIRE FOR CHILDREN WITH INFLAMMATORY BOWEL DISEASE</description>
            <units>Score units</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="146.6" spread="12.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change after 12 weeks</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.2" spread="8.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>12 weeks</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="147.0" spread="15.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Event</title>
        <description>Any kind of adverse event</description>
        <time_frame>16 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Entocort</title>
            <description>Entocort 6 mg/day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Adverse Event</title>
            <description>Any kind of adverse event</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="37"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 weeks</time_frame>
      <desc>12 weeks on 6 mg/day followed by 2 weeks on 3 mg/day and 2 weeks without active drug</desc>
      <group_list>
        <group group_id="E1">
          <title>Entocort</title>
          <description>Entocort 6 mg/day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemhorrage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Ileal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Cushingoid</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Haematochizia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hirsutism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tore Persson, Study Statistician</name_or_title>
      <organization>AstraZeneca R&amp;D Mölndal</organization>
      <phone>+463177766069 ext 66069</phone>
      <email>tore.teb.persson@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
